This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Sunesis Pharmaceuticals, Inc.
Drug Names(s): AG-7352, SNS-595, voreloxin
Description: Voreloxin is a quinolone derivative that selectively targets cells undergoing DNA synthesis to induce the rapid onset of cell death and G2 cell cycle arrest. The molecule intercalates DNA and inhibits topoisomerase II. It is a member of a class of compounds known as naphthyridines.
Sunesis and Dainippon
Sunesis Pharmaceuticals announced on October 15, 2003 that the Company has entered into an agreement with Dainippon Pharmaceutical to acquire exclusive worldwide development and marketing rights for Dainippon's voreloxin. Under the terms of this agreement, Sunesis will make an up-front payment and a series of milestone payments based on successful development and approval of voreloxin. Sunesis will also make royalty payments based on net sales. In return, Sunesis will receive an exclusive, worldwide license. No additional terms were disclosed.
Sunesis and Royalty Pharma
In March 2012, Royalty Pharma and Sunesis announced that Royalty Pharma has agreed to pay Sunesis $25 million, under certain circumstances related to the successful development of Sunesis vosaroxin, to acquire a royalty on future worldwide net sales of vosaroxin.
Under terms of the agreement, Royalty Pharma will invest $25 million immediately following VALORs interim...See full deal structure in Biomedtracker
Partners: Sumitomo Dainippon Pharma Co., Ltd.
Additional information available to subscribers only: